Although, CXCL13 has been reported in many types of carcinomas to drive signaling pathways associated with proliferation and invasive, including PI3K/AKT pathway49 and Wnt/beta-catenin signaling pathway50, in patients with HER2-positive BC or TNBC, increased CXCL13 corresponded with better survival51. Here, ERBB2 is linked to breast cancer.